Skip to main content

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Enovix Corporation (ENVX)

Law Offices of Howard G. Smith reminds investors of the upcoming March 7, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX) common stock between February 22, 2021 and January 3, 2023, inclusive (the “Class Period”), including those who purchased Rodgers Silicon Valley Acquisition Corp. (“RSVAC”) common stock prior to July 15, 2021.

Investors suffering losses on their Enovix investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On July 15, 2021, Enovix became a public entity via business combination with RSVAC, a special purpose acquisition company.

On November 1, 2022, Enovix released its third quarter 2022 financial results, revealing that the Company had realized only $8,000 in revenue that quarter. Furthermore, it revealed that it would be “dialing back” its work on improving the Company’s Gen1 lines in favor of shifting its focus to future Gen2 lines because the supposed improvements were not having the desired results on output. Enovix also stated that it “anticipate[d] achieving lower overall output from Fab-1 in 2023.”

On this news, Enovix’s stock price fell $8.34, or 44.2%, to close at $10.53 per share on November 2, 2022, thereby injuring investors.

Then, on January 3, 2023, the Company’s Executive Chairman revealed in a special presentation that the Company’s second production facility and Gen2 lines would be delayed by several months because of equipment failures.

On this news, Enovix’s stock price fell $4.97, or 41%, to close at $7.15 on January 4, 2023, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants overstated Enovix’s ability to produce batteries at scale and its ability to deliver batteries ahead of competition.

If you purchased or otherwise acquired Enovix common stock during the Class Period, you may move the Court no later than March 7, 2023 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.